Omega Therapeutics Inc (OMGA) - Total Liabilities
Based on the latest financial reports, Omega Therapeutics Inc (OMGA) has total liabilities worth $141.18 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Omega Therapeutics Inc to assess how effectively this company generates cash.
Omega Therapeutics Inc - Total Liabilities Trend (2019–2023)
This chart illustrates how Omega Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check Omega Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Omega Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Omega Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oragenics Inc
NYSE MKT:OGEN
|
USA | $1.79 Million |
|
Multipolar Tbk
JK:MLPL
|
Indonesia | Rp8.06 Trillion |
|
Brooks Macdonald Group
LSE:BRK
|
UK | GBX78.21 Million |
|
Henry Boot PLC
LSE:BOOT
|
UK | GBX208.79 Million |
|
X2M Connect Ltd
AU:X2M
|
Australia | AU$9.26 Million |
|
Wescan Goldfields Inc
V:WGF
|
Canada | CA$453.87K |
|
Sherborne Investors Guernsey C Ltd
LSE:SIGC
|
UK | GBX38.06K |
|
Olivers Real Food Ltd
AU:OLI
|
Australia | AU$29.67 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down Omega Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OMGA company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 12.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Omega Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Omega Therapeutics Inc (2019–2023)
The table below shows the annual total liabilities of Omega Therapeutics Inc from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $146.35 Million | +265.63% |
| 2022-12-31 | $40.03 Million | +22.39% |
| 2021-12-31 | $32.70 Million | -64.72% |
| 2020-12-31 | $92.71 Million | +120.54% |
| 2019-12-31 | $42.04 Million | -- |
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more